PON1(Serum paraoxonase/arylesterase 1) Introduction

PON1 (paraoxonase 1) is also a major anti-atherosclerotic component of high-density lipoprotein (HDL). The PON1 gene is activated by PPAR-γ, which increases synthesis and release of paraoxonase 1 enzyme from the liver, reducing atherosclerosis.  The "natural" substrates for PON1 appear to be lactones. However, PON1 has evolved to be a highly promiscuous enzyme capable of hydrolysing a wide variety of substrates such as lactones (including a number of important pharmaceutical agents such as statins), glucuronide drugs, thiolactones, arylesters, cyclic carbonates, organophosphorus pesticides and nerve gases such as sarin, soman and VX, oestrogen esters and lipid peroxides (oxidised lipids). 

Human PON1(Serum paraoxonase/arylesterase 1)  ELISA Kit Test method

This kit uses sandwich ELISA to detect the concentration of PON1(Serum paraoxonase/arylesterase 1). PON1(Serum paraoxonase/arylesterase 1) ELISA Kit allows for the in vitro quantitative determination of PON1(Serum paraoxonase/arylesterase 1) concentrations in serum, plasma, tissue homogenates and other biological fluids. The concentration gradients of the kit standards or positive controls render a theoretical kit detection range in biological research samples containing PON1(Serum paraoxonase/arylesterase 1). 

Reference:

1,  GRCm38: Ensembl release 89: ENSMUSG00000002588 - Ensembl, May 2017

2. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.